Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a significant pipeline and array of products focused on ophthalmic conditions. For glaucoma and ocular hypertension, their drug candidates encompass DE-111, currently undergoing Phase III clinical evaluation; DE-117, which is available in Japan; DE-126, now in Phase IIb trials; DE-128, being developed for European markets and also in Phase II/III trials within the United States; and DE-130A, another compound advancing through Phase III clinical trials. Santen's development efforts also extend to treatments for other eye ailments: DE-114A for allergic conjunctivitis, DE-076C to address vernal keratoconjunctivitis, and DE-109, a therapy for uveitis that is in Phase III trials. Furthermore, their initiatives against myopia include DE-127, which is simultaneously in Phase II/III clinical trials in Japan and Phase III across Asia, alongside STN1013400, currently in its initial Phase I clinical trials for the same condition. They also offer DE-089C, a treatment for dry eye that has successfully completed its Phase III clinical trials. Beyond prescription medications, Santen also supplies a selection of over-the-counter pharmaceutical products. The corporation, founded in Osaka, Japan, in 1890, was initially known as Santendo Pharmaceutical Co., Ltd. before formally adopting its current name, Santen Pharmaceutical Co., Ltd., in 1958.